Previous close | 4.99 |
Open | 4.99 |
Bid | 5.06 x 800 |
Ask | 5.09 x 1300 |
Day's range | 4.96 - 5.09 |
52-week range | 1.87 - 5.70 |
Volume | |
Avg. volume | 915,285 |
Market cap | 700.557M |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.33 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.79 |
LANGHORNE, Pa., May 09, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update.
LANGHORNE, Pa., May 07, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
LANGHORNE, Pa., April 08, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA.